Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3894744
Max Phase: Preclinical
Molecular Formula: C21H36O4
Molecular Weight: 352.52
Molecule Type: Small molecule
Associated Items:
ID: ALA3894744
Max Phase: Preclinical
Molecular Formula: C21H36O4
Molecular Weight: 352.52
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCC[C@@H]1OC(=O)C(C)=C1C(=O)O
Standard InChI: InChI=1S/C21H36O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-19(20(22)23)17(2)21(24)25-18/h18H,3-16H2,1-2H3,(H,22,23)/t18-/m0/s1
Standard InChI Key: SYVOXIHVISVSED-SFHVURJKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 352.52 | Molecular Weight (Monoisotopic): 352.2614 | AlogP: 5.79 | #Rotatable Bonds: 15 |
Polar Surface Area: 63.60 | Molecular Species: ACID | HBA: 3 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 3.38 | CX Basic pKa: | CX LogP: 7.09 | CX LogD: 3.68 |
Aromatic Rings: 0 | Heavy Atoms: 25 | QED Weighted: 0.30 | Np Likeness Score: 1.02 |
1. Sweidan A, Chollet-Krugler M, van de Weghe P, Chokr A, Tomasi S, Bonnaure-Mallet M, Bousarghin L.. (2016) Design, synthesis and biological evaluation of potential antibacterial butyrolactones., 24 (22): [PMID:27687969] [10.1016/j.bmc.2016.09.040] |
Source(1):